ALKERMES | ALKS - Ordinary Share Capital


ALKERMES reported $165.1M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
ALKERMES USD 165.1M 49K Sep/2025
Amgen USD 538M 300K Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 0 Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
J&J USD 2.41B 584K Sep/2025
Malin Corporation EUR 200K 0 Dec/2024
Merck USD 2.5B 715.14M Jun/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Otsuka Holdings JPY 528.13M 0 Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025